Stratec Q2 Earnings Call Highlights

Stratec (ETR:SBS) said its second-quarter performance improved significantly from a weak start to 2026, helping narrow its year-on-year sales and earnings gap in the first half. The company maintained its full-year guidance despite lower demand for service parts and consumables and an expectation that results will again be heavily weighted toward the fourth quarter.

First-half revenue totaled EUR 112.5 million, down 5.1% on a reported basis and 3.3% at constant currency, CFO Tanja Bücherl said. The company reported adjusted EBIT of EUR 7.7 million, compared with EUR 8.5 million a year earlier, while the adjusted EBIT margin declined modestly to 6.9% from 7.2%.

Reported EBIT under IFRS was about EUR 5.5 million, while adjusted net income was EUR 4.1 million, or EUR 0.34 per share. Reported IFRS net income was EUR 2.4 million, or EUR 0.20 per share.

Systems Growth Offset by Service Parts Weakness

Revenue trends differed substantially across Stratec’s operating areas. System revenue rose 15.4% at constant currency to EUR 39.7 million, supported by demand in immunoassay, molecular diagnostics and immunohematology.

However, revenue from service parts and consumables fell 11.9% at constant currency to EUR 46.1 million. Bücherl attributed the decline mainly to inventory optimization by several major customers seeking to improve working capital. Development and services revenue also fell 7.8% at constant currency, reflecting a challenging comparison against a strong prior-year period.

CEO Marcus Wolfinger said maintenance parts and spares had been “exceptionally weak,” even as utilization of diagnostic equipment in molecular diagnostics, immunoassay and immunohematology remained high or was improving. He said the weakness was concentrated among customers that had undergone merger-and-acquisition activity over the past year, with new owners reviewing service inventory levels.

Wolfinger said Stratec does not believe the shortfall primarily reflects customers turning to unapproved third-party maintenance components. He cited regulatory and risk considerations surrounding the use of such parts in diagnostic systems. He added that plastic consumables were outperforming, albeit from a low base.

The weaker mix weighed on profitability because service parts and consumables have historically carried higher margins. Still, the company said cost discipline, structural adjustments and exchange-rate effects helped limit the impact. In the second quarter, adjusted EBIT rose more than 125% to EUR 7 million and the adjusted EBIT margin increased to 11.9% from 5.4% in the first quarter.

Cash Flow and Balance Sheet Improve

Stratec generated operating cash flow of EUR 29.7 million in the first half, compared with negative operating cash flow of EUR 5.8 million a year earlier. Free cash flow was EUR 23.5 million, versus negative EUR 14.7 million in the prior-year period.

Bücherl said the improvement was driven particularly by lower accounts receivable and lower tax payments. The company used the cash generation to invest, reduce debt and pay its dividend, she said.

Net debt declined to EUR 96.7 million, while the ratio of net debt to last-12-month EBITDA improved to 2.9 from 3.3 at the end of 2025. The equity ratio rose to 58.1%.

Management said working-capital management remains a priority, particularly inventories. Wolfinger said inventory levels remain elevated partly because Stratec has made last-time purchases of certain components to support products that cannot easily be redesigned or replaced, including certain electronic components, cameras and lenses. Some newer products also have lower-than-expected ramp-up rates, limiting the company’s ability to reduce inventory.

Guidance Maintained as Fourth Quarter Expected to Dominate

Stratec reaffirmed its 2026 outlook for constant-currency revenue growth in the medium- to high-single-digit percentage range and an adjusted EBIT margin approximately in line with the prior year’s 10% level.

Wolfinger said the forecast depends heavily on year-end business. The fourth quarter accounted for roughly 30% to 33% of annual sales in recent years, and management expects the contribution in 2026 to be closer to 34% to 35%. Third-quarter revenue is expected to be in a similar absolute range as the second quarter, he said.

The company continues to target an investment ratio of 6.5% to 8.5% of sales, though first-half capital expenditures represented 5.5% of revenue. Bücherl said Stratec is monitoring business conditions closely and is seeking to avoid premature investments.

Wolfinger said the company is also addressing longer lead times and higher prices for electronics-related components. Stratec has increased its monitoring of long-lead-time items and said it is using contractual arrangements with customers to address exceptional input-cost pressures where possible.

Lifecycle Management and Longer-Term Targets

Management said customer demand for lifecycle-management projects remains high, increasingly driven by regulatory, cybersecurity and software-renewal requirements rather than by efforts to extend product lifecycles alone. Wolfinger said software development and related verification activities are operating at or above capacity as customers address legacy-product requirements.

For the 2025-to-2028 period, Stratec continues to expect compound annual revenue growth of 6% to 8%, followed by an acceleration to 10% to 12% from 2028 to 2030 as newer products reach the market. The company reiterated targets for an adjusted EBIT margin of at least 13% by 2028 and at least 15% by 2030.

Wolfinger said expectations for molecular diagnostics market recovery have moderated. While run rates are improving, he said the market remains below pre-pandemic levels and more saturated than previously expected. He also said Stratec’s Natech business is making progress but remains behind the company’s original post-merger integration plans. No additional earn-out payments have been made beyond the acquisition price, he said.

About Stratec (ETR:SBS)

Stratec SE, together with its subsidiaries, designs and manufactures automation and instrumentation solutions in the fields of in-vitro diagnostics and life sciences in Germany, European Union, and internationally. It designs and manufactures automated analyzer systems for clinical diagnostics and biotechnology customers; and offers complex consumables for diagnostics and medical applications. The company was formerly known as Stratec Biomedical AG and changed its name to Stratec SE in December 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Where Should You Invest $1,000 Right Now?

Before you make your next trade, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.

They believe these five stocks are the five best companies for investors to buy now...

See The Five Stocks Here

Source MarketBeat